A New Trend in Early-Phase CNS Trials

Watch this on-demand webinar on which we collaborated with Cambridge Cognition, to learn about the important role of cognitive and pharmacodynamic testing in first-in-human (FIH) trials for novel CNS-active drugs.

Recently, we have seen increasing numbers of complex FIH studies in CNS-active drugs to gather comprehensive data with a wider range of doses as early as possible. Insights in FIH studies provide valuable information on potential dosing, efficacy, and safety, and serve as a good guide for the regulatory requirements needed throughout clinical development.

WATCH THE VIDEO

You may also be interested in these resources:

Webpage:

• CNS Drug Development Solutions

Webinars:

• Inside the Pharmacodynamic Toolbox
• A Review of the FDA's Psychedelic Clinical Research Guidances

Maximize Sterility With Terminal Sterilization

Did you know terminal sterilization is the most effective way to reduce the chances of microbial contamination? In fact, it provides a higher level of sterility assurance to finished drug products over aseptic manufacturing.

Browse this comprehensive webpage to discover the full benefits of terminally sterilizing your pharmaceutical products, regulatory agency preferences, and how to evaluate your product’s compatibility.

This webinar and scientific article on the topic may also interest you.

Questions? Speak with one of our experts.

Other related resources:

• Webpage: Altasciences’ Manufacturing and Analytical Testing Solutions
• Webinar: Nanomilling for Enhanced Solubility and Bioavailability

Optimizing Preclinical Study Designs to Reduce Animal Use

Our latest webinar is now available on-demand―watch it at your leisure.

This webinar focuses on the methods employed to minimize the number of animals used in toxicology studies while ensuring scientific integrity and reproducible findings. Drawing from our extensive experience spanning decades, we analyze the advantages and limitations of each method.

WATCH IT NOW!

Questions? Speak with one of our experts today and let's get your program underway.

​​Related resources that may interest you:

• Scientific Poster: Comparison of Safety Pharmacology Endpoints Used on Toxicology Studies Across Differing Cynomolgus Monkey Origins
• Webpage: Pivotal Toxicology Study Solutions
• Webpage: Comprehensive Preclinical Research Services

On June 12, Altascientists at all nine of our facilities took time to celebrate each other and the important work that we do as your partners. Altasciences Day, as we like to call it, is a testament to our journey with you—a journey defined by collaboration, dedication, and moving in unison.

I want to extend my heartfelt gratitude for your ongoing trust and partnership, and for giving us the opportunity to help you bring better drugs to the people who need them, faster.

Here’s to many more remarkable accomplishments, and even more reasons to celebrate.

Cheers,

Chris Perkin
CEO, Altasciences

Your Trusted CDMO Partner From Discovery to Market

Altasciences offers extensive oral solid dose manufacturing services, including formulation development, preclinical and clinical batch supply, as well as scale-up to commercial manufacturing. Our skilled scientific experts collaborate with you to create customized formulations and streamline production procedures to produce a wide range of high-quality oral solid dosage forms that are safe, efficient, and cost-effective.

Explore our full range of manufacturing solutions:

• Formulation development
• Tablets
• Powder-filled capsules
• Liquid-filled capsules
• Over-encapsulation
• Solubility enhancement
• Terminal sterilization
• High potency manufacturing
• Analytical testing

Questions? Speak with one of our experts.

You may also be interested in:

• Infographic: Choosing the Optimal Dosage Form for Your Molecule
• Webinar: Overcoming the Challenges of Manufacturing for Clinical Trials
• Podcast: Ensuring Successful Formulation for Nonclinical Testing